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This special issue focuses on erythrocytes and erythropoietin
including original research and review articles on the cellular
physiology of erythrocytes and of erythrocyte-associated
disorders. Moreover, the special issue includes papers on the
action of erythropoietin and hypoxia-inducible factors on a
cellular level. In the following, we present the original papers
published in this special edition.
D. Barneaud-Rocca et al. deal with one of the most abun-
dant proteins in red blood cells, the band 3 protein (Anion
Exchanger 1). The paper reviews recent work hypothesizing
the contribution of band 3 point mutations to a sodium and
potassium leak. It is compared to alternative explanations
suggesting that point mutations in band 3 regulate the cation
leak through other transporters. The topic is driven by
the fact that mutations in the band 3 protein have been
associated with hereditary stomatocytosis. The molecular
mechanisms discussed in the paper link the stomatocytosis
and the sodium potassium leak of the mutated band 3
protein.
W. Nunomura et al. review the function of unstructured
N-terminal domain of protein 4.1R and 4.1G and charac-
terize the binding proﬁles of proteins 4.1R80, 4.1R135 and
protein 4.1G in erythropoiesis. The regulation of the binding
proﬁles of these proteins by the presence or absence of the N-
terminal 209 amino acid sequence (headpiece region (HP))
andunstruct ur edd o maino fthep r ot e inasw ellaso f4.1R135
(which contains the HP) by both Ca2+ and Ca2+/CaM is
discussed. Knowing the diﬀerent regulation and expression
of the 4.1 protein isoforms will foster our understanding of
erythropoiesis.
F. Fares et al. fused one Carboxyl-Terminal Peptide
(CTP) of the human chorionic gonadotropin beta subunit
to the N-terminal end and two CTPs to the C-terminal
end of erythropoietin (Epo). This artiﬁcial erythropoiesis-
stimulating agent had increased in vivo activity as well as
half-life compared with recombinant human Epo and the
hyperglycosylated Epo analogue darbepoetin alfa (Aranesp).
As erythropoiesis-stimulating agents often need to be
injected repeatedly over long time periods, for example, for
anemiatreatmentinkidneydiseasesorcancer,moreeﬀective
andlongerlastingEpoderivatesimprovethepatients’quality
of life.
E. Straface et al. present the results of a pilot study inves-
tigating new peripheral sex-associated markers in patients
with metabolic syndrome and subclinical atherosclerosis.
The metabolic syndrome, which is characteristic of hyper-
tension, obesity, insulin resistance, hypertriglyceridemia,
and hypercholesterolemia, is a major risk factor for car-
diovascular mortality in the developed world. In their
study, E. Straface et al. analyzed glycophorin A, CD47,
and phosphatidylserine exposition at the cell surface as
hallmarks of erythrocyte damage. They report signiﬁcant
gender diﬀerences of those parameters in patients with
metabolic syndrome.
L. J. Norton et al. review the recent advance in cellular
reprogramming with the particular emphasis on its poten-
tially beneﬁcial use for the future treatment of hemoglobi-
nopathies. Typical and frequent hemoglobinopathies are
genetic disorders such as thalassaemia and sickle cell disease.
To date, blood transfusion is the principal therapy of those2 International Journal of Cell Biology
diseases. In their review article, L. J. Norton et al. outline
the recent development in stem cell research such as classic
cellular reprogramming and transdiﬀerentiation and discuss
their potential application for the treatment of anemia
following hemoglobinopathies.
We hope that this special issue will alert researchers
to some recent development in the ﬁeld of erythrocytes
and erythropoietin, particularly the correlation between
protein alterations and clinical symptoms, and that a better
understanding of this correlation can direct our eﬀorts to the
discovery of new therapeutic strategies for the treatment of
anemia and metabolic disorders.
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